These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34120809)

  • 1. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients.
    Helvind NM; Aros Mardones CA; Hölmich LR; Hendel HW; Bidstrup PE; Sørensen JA; Chakera AH
    Eur J Surg Oncol; 2021 Dec; 47(12):3020-3027. PubMed ID: 34120809
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
    J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
    Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
    Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
    J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
    Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
    Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
    Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Te Marvelde L; Herschtal A; Spillane J; Gyorki D; Speakman D; Estall V; Donahoe S; Pohl M; Pope K; Chua M; Sandhu S; McArthur GA; McCormack CJ; Henderson M; Hicks RJ; Shackleton M
    Ann Oncol; 2018 Jul; 29(7):1569-1574. PubMed ID: 29659679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of PET/CT in patients with stage I-III melanoma.
    Avilés Izquierdo JA; Molina López I; Sobrini Morillo P; Márquez Rodas I; Mercader Cidoncha E
    Clin Transl Oncol; 2020 Aug; 22(8):1414-1417. PubMed ID: 31873917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of lymph node ultrasound and whole body
    Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
    Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
    Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma.
    Ravichandran S; Nath N; Jones DC; Li G; Suresh V; Brys AK; Hanks BA; Beasley GM; Salama AKS; Howard BA; Mosca PJ
    Surg Oncol; 2020 Dec; 35():533-539. PubMed ID: 33161362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.
    Nijhuis AAG; Dieng M; Khanna N; Lord SJ; Dalton J; Menzies AM; Turner RM; Allen J; Saw RPM; Nieweg OE; Thompson JF; Morton RL
    Ann Surg Oncol; 2019 Jun; 26(6):1860-1868. PubMed ID: 30911946
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
    Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
    Madu MF; Timmerman P; Wouters MWJM; van der Hiel B; van der Hage JA; van Akkooi ACJ
    Melanoma Res; 2017 Jun; 27(3):251-257. PubMed ID: 28225434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
    Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
    Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
    J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
    Andersen JAS; Spatzek AD; Vilstrup MH; Grupe P; Hess S; Holdgaard PC; Bastholt L; Gerke O; Hildebrandt MG
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2342-2351. PubMed ID: 35129651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
    Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL
    Ann Surg Oncol; 2021 Aug; 28(8):4561-4569. PubMed ID: 33393039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.